Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 16/20 | 0.77 |
| ▸ | PAK3 | O75914 | 14/20 | 0.77 |
| ▸ | PAK2 | Q13177 | 14/20 | 0.77 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.58 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.53 |
| ▸ | IDH1 | O75874 | 1/20 | 0.47 |
| ▸ | PAK4 | O96013 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15216448 | 1.00 | PAK1 (0.77) | PAK1PAK3PAK2NTRK1PKN1 | |
| SCHEMBL15216612 | 1.00 | PAK1 (0.77) | PAK1PAK3PAK2NTRK1PKN1 | |
| SCHEMBL15216613 | 1.00 | PAK1 (0.77) | PAK1PAK3PAK2NTRK1PKN1 | |
| SCHEMBL15208751 | 1.00 | PAK1 (0.77) | PAK1PAK3PAK2NTRK1PKN1 | |
| SCHEMBL14723174 | 0.88 | PAK1 (0.93) | PAK1PAK3PAK2NTRK1PAK4 | |
| SCHEMBL15209625 | 0.88 | PAK1 (0.93) | PAK1PAK3PAK2NTRK1PAK4 | |
| SCHEMBL15209021 | 0.88 | PAK1 (0.82) | PAK1PAK3PAK2NTRK1IDH1 | |
| SCHEMBL15216435 | 0.87 | PAK1 (0.75) | PAK1PAK3PAK2NTRK1IDH1 | |
| SCHEMBL15216439 | 0.87 | PAK1 (0.71) | PAK1PAK3PAK2NTRK1PKN1 | |
| SCHEMBL15216440 | 0.87 | PAK1 (0.71) | PAK1PAK3PAK2NTRK1PKN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | PAK1 1/4885PAK3 6/4885PAK2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.